Last reviewed · How we verify
Phexxi
Phexxi is a marketed drug by Queen's Medical Center, positioned in the contraceptive market. The key composition patent expires in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the lack of revenue data, which limits the ability to assess its commercial performance and market impact.
At a glance
| Generic name | Phexxi |
|---|---|
| Sponsor | Queen's Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome (EARLY_PHASE1)
- Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel (PHASE3)
- AMP002 Phase III Contraceptive Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phexxi CI brief — competitive landscape report
- Phexxi updates RSS · CI watch RSS
- Queen's Medical Center portfolio CI